Logo image of AKTX

AKARI THERAPEUTICS PLC-ADR (AKTX) Stock Fundamental Analysis

NASDAQ:AKTX - Nasdaq - US00972G2075 - ADR - Currency: USD

0.99  -0.02 (-1.98%)

After market: 1.0299 +0.04 (+4.03%)

Fundamental Rating

1

Taking everything into account, AKTX scores 1 out of 10 in our fundamental rating. AKTX was compared to 551 industry peers in the Biotechnology industry. Both the profitability and financial health of AKTX have multiple concerns. AKTX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

AKTX had negative earnings in the past year.
AKTX had a negative operating cash flow in the past year.
In the past 5 years AKTX always reported negative net income.
AKTX had a negative operating cash flow in each of the past 5 years.
AKTX Yearly Net Income VS EBIT VS OCF VS FCFAKTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

The Return On Assets of AKTX (-39.14%) is comparable to the rest of the industry.
AKTX has a Return On Equity (-89.03%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -39.14%
ROE -89.03%
ROIC N/A
ROA(3y)-132.43%
ROA(5y)-132.76%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AKTX Yearly ROA, ROE, ROICAKTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50K -100K -150K

1.3 Margins

AKTX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AKTX Yearly Profit, Operating, Gross MarginsAKTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

0

2. Health

2.1 Basic Checks

The debt/assets ratio for AKTX is higher compared to a year ago.
AKTX Yearly Shares OutstandingAKTX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M
AKTX Yearly Total Debt VS Total AssetsAKTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

Based on the Altman-Z score of -6.27, we must say that AKTX is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -6.27, AKTX is doing worse than 64.97% of the companies in the same industry.
AKTX has a Debt/Equity ratio of 0.15. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.15, AKTX is doing worse than 67.51% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.15
Debt/FCF N/A
Altman-Z -6.27
ROIC/WACCN/A
WACCN/A
AKTX Yearly LT Debt VS Equity VS FCFAKTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

AKTX has a Current Ratio of 0.15. This is a bad value and indicates that AKTX is not financially healthy enough and could expect problems in meeting its short term obligations.
AKTX's Current ratio of 0.15 is on the low side compared to the rest of the industry. AKTX is outperformed by 96.19% of its industry peers.
A Quick Ratio of 0.15 indicates that AKTX may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.15, AKTX is doing worse than 96.01% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.15
Quick Ratio 0.15
AKTX Yearly Current Assets VS Current LiabilitesAKTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

1

3. Growth

3.1 Past

AKTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 20.00%, which is quite good.
EPS 1Y (TTM)20%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%90%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

AKTX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 23.15% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y86.76%
EPS Next 2Y37.2%
EPS Next 3Y23.15%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
AKTX Yearly Revenue VS EstimatesAKTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2025 2026 2027 2028 2029 2030 50M 100M
AKTX Yearly EPS VS EstimatesAKTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -10 -20 -30 -40

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

AKTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AKTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AKTX Price Earnings VS Forward Price EarningsAKTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AKTX Per share dataAKTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as AKTX's earnings are expected to grow with 23.15% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y37.2%
EPS Next 3Y23.15%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AKTX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AKARI THERAPEUTICS PLC-ADR

NASDAQ:AKTX (8/8/2025, 8:18:43 PM)

After market: 1.0299 +0.04 (+4.03%)

0.99

-0.02 (-1.98%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2025-05-13
Earnings (Next)08-18 2025-08-18
Inst Owners0.98%
Inst Owner Change-8.19%
Ins Owners34.4%
Ins Owner Change0.08%
Market Cap31.85M
Analysts82.86
Price Target7.14 (621.21%)
Short Float %17.47%
Short Ratio1.69
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-91.25%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)87.5%
EPS NY rev (3m)87.5%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.43
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.21
EYN/A
EPS(NY)-0.46
Fwd EYN/A
FCF(TTM)-0.39
FCFYN/A
OCF(TTM)-0.39
OCFYN/A
SpS0
BVpS0.69
TBVpS-0.79
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -39.14%
ROE -89.03%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-132.43%
ROA(5y)-132.76%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.15
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.15
Quick Ratio 0.15
Altman-Z -6.27
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)20%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%90%
EPS Next Y86.76%
EPS Next 2Y37.2%
EPS Next 3Y23.15%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y0.95%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y23.61%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y23.61%
OCF growth 3YN/A
OCF growth 5YN/A